Qualitative study on decision-making by prostate cancer physicians during active surveillance

Uro-Oncology

Personalized Biopsy Schedules Based on Risk of Gleason Upgrading for Low-Risk Prostate Cancer Active Surveillance Patients

BJU Int.

Tomer A, Nieboer D, Roobol MJ, Bjartell A, Steyerberg EW, Rizopoulos D, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium

doi: 10.1111/bju.15136.

Uro-Oncology

Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS)

J Urol.

Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW

doi: 10.1016/j.juro.2018.07.065.

Uro-Oncology

Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes

Eur Urol.

Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y

doi: 10.1016/j.eururo.2018.01.017.

Uro-Oncology

Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study

Eur Urol.

Stavrinides V, Giganti F, Trock B, Punwani S, Allen C, Kirkham A, Freeman A, Haider A, Ball R, McCartan N, Whitaker H, Orczyk C, Emberton M, Moore CM

doi: 10.1016/j.eururo.2020.03.035.

Uro-Oncology

Prostate cancer adverse pathology reclassification in patients undergoing active surveillance in a long-term follow-up series

Prostate.

Fernández-Conejo G, Hernández V, Guijarro A, de la Peña E, Inés A, Pérez-Fernández E, Llorente C

doi: 10.1002/pros.23933.

Uro-Oncology

Prostate Health Index and Multiparametric MRI to Predict Prostate Cancer Grade Reclassification in Active Surveillance

BJU Int.

Schwen ZR, Mamawala M, Tosoian JJ, Druskin SC, Ross AE, Sokoll LJ, Epstein JI, Carter HB, Gorin MA, Pavlovich CP

doi: 10.1111/bju.15101.

Uro-Oncology

Active Surveillance of Prostate Cancer is a Viable Option in Men Younger Than 60 Years

J Urol.

Salari K, Kuppermann D, Preston MA, Dahl DM, Efstathiou JA, Blute ML, Vesprini D, Loblaw A, Zietman AL, Klotz L, Feldman AS

doi: 10.1097/JU.

Uro-Oncology

Evaluating the Trade-offs Men with Localised Prostate Cancer Make Between the Risks and Benefits of Treatments: The COMPARE Study

J Urol.

Watson V, McCartan N, Krucien N, Abu V, Ikenwilo D, Emberton M, Ahmed HU

doi: 10.1097/JU.0000000000000754.

Further Publications UrologyFurther Publications Gynecology

A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance

Prostate.

Jarrard D, Filon M, Huang W, Havighurst T, DeShong K, Kim K, Konety BR, Saltzstein D, Mukhtar H, Wollmer B, Suen C, House MG, Parnes HL, Bailey HH

doi: 10.1002/pros.24076.

Related content

Personalized Biopsy Schedules Based on Risk of Gleason Upgrading for Low-Risk Prostate Cancer Active Surveillance Patients

Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS)

Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes

Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study

Prostate cancer adverse pathology reclassification in patients undergoing active surveillance in a long-term follow-up series

Prostate Health Index and Multiparametric MRI to Predict Prostate Cancer Grade Reclassification in Active Surveillance

Active Surveillance of Prostate Cancer is a Viable Option in Men Younger Than 60 Years

Evaluating the Trade-offs Men with Localised Prostate Cancer Make Between the Risks and Benefits of Treatments: The COMPARE Study

A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance